Recordati
Recordati S.p.A. is an international pharmaceutical group based in Italy focused on the research, development, manufacturing, and marketing of specialty medicines and rare disease treatments. The company operates through Specialty & Primary Care and Rare Diseases segments, producing cardiovascular, urological, metabolic, and orphan drug formulations. Principal revenues stem from commercial sales of proprietary prescription pharmaceuticals, specialty healthcare treatments, and active pharmaceutical ingredients. Recordati serves primary care physicians, medical specialists, hospitals, pharmacies, and patients across Europe, the Americas, and international markets. The group holds a distinct global market position as a recognized specialist in orphan drugs for rare metabolic and endocrine disorders. Recordati S.p.A. is headquartered in Milan, Italy, and its ordinary shares are listed on the Euronext Milan exchange.
40 of the funds FundTelligence covers report a position in Recordati.
- Legal name
- Recordati S.p.A.
- Sector
- Health Care
- Country
- Italy
- Funds holding it
- 40
Funds holding Recordati
- Carnegie Global Resilient Small Cap — Carnegie · 3.17 % (full portfolio disclosed, June 2026)
- Handelsbanken Europa Index Criteria — Handelsbanken · 0.48 % (full portfolio disclosed, October 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 0.36 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 0.25 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Utbytte — Handelsbanken · 0.2 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Högutdelande Criteria — Handelsbanken · 0.2 % (full portfolio disclosed, October 2026)
- Nordea Discretionary Global Equity — Nordea Funds · 0.09 % (full portfolio disclosed, July 2026)
- Nordea PM Globale Aktier Strategi — Nordea Funds · 0.09 % (full portfolio disclosed, July 2026)
Showing the 8 largest of 40 funds holding it.